Advertisement

Ketamine pp 1-14 | Cite as

Ketamine Abuse: Past and Present

  • Ming-Chyi Huang
  • Shih-Ku LinEmail author
Chapter
  • 43 Downloads

Abstract

Ketamine is an anesthetic derivative of phencyclidine with dissociative, analgesic, and psychedelic properties. It is extensively used as an anesthetic drug in surgical procedures in pediatric, obstetric, and geriatric patients, as well as in veterinary settings. Since its approval for clinical use, the misuse and abuse of ketamine have been reported in scientific journals and in popular media globally, particularly in the last two decades. It has been used as a common club drug in dance, rave, and squat party scenes. Owing to its unique pharmacological properties, ketamine has been used as an antidepressant for the treatment of resistant depression. However, a long-term use of high doses of ketamine leads to numerous physical and psychological negative effects, such as abdominal pain, urinary system disorder, dependence/tolerance/withdrawal, cognitive impairment, psychosis, and depression. At present, no effective pharmacotherapy for managing compulsive drug-seeking behavior in patients with ketamine use disorder is available. Treatment that incorporates regular urine screening in addition to medications for psychiatric symptoms and craving may present favorable results.

Keywords

Abuse K-hole Physical consequence Psychological consequence Regulation Treatment 

References

  1. Abi-Saab WM, D’Souza DC, Moghaddam B, Krystal JH (1998) The NMDA antagonist model for schizophrenia: promise and pitfalls. Pharmacopsychiatry 31(Suppl 2):104–109PubMedCrossRefGoogle Scholar
  2. Adler CM, Goldberg TE, Malhotra AK, Pickar D, Breier A (1998) Effects of ketamine on thought disorder, working memory, and semantic memory in healthy volunteers. Biol Psychiatry 43:811–816PubMedCrossRefGoogle Scholar
  3. Ahmed SN, Petchkovsky L (1980) Abuse of ketamine. Br J Psychiatry 137:303PubMedCrossRefGoogle Scholar
  4. Bang M, Kim KR, Song YY, Baek S, Lee E, An SK (2015) Neurocognitive impairments in individuals at ultra-high risk for psychosis: who will really convert? Aust N Z J Psychiatry 49:462–470PubMedCrossRefGoogle Scholar
  5. Berman RM, Cappiello A, Anand A, Oren DA, Heninger GR, Charney DS, Krystal JH (2000) Antidepressant effects of ketamine in depressed patients. Biol Psychiatry 47:351–354Google Scholar
  6. Bokor G, Anderson PD (2014) Ketamine: an update on its abuse. J Pharm Pract 27:582–586PubMedCrossRefGoogle Scholar
  7. Breier A, Malhotra AK, Pinals DA, Weisenfeld NI, Pickar D (1997) Association of ketamine-induced psychosis with focal activation of the prefrontal cortex in healthy volunteers. Am J Psychiatry 154:805–811CrossRefGoogle Scholar
  8. Carmona-Huerta J, Castiello-De Obeso S, Ramirez-Palomino J, Duran-Gutierrez R, Cardona-Muller D, Grover-Paez F, Fernandez-Dorantes P, Medina-Davalos R (2019) Polypharmacy in a hospitalized psychiatric population: risk estimation and damage quantification. BMC Psychiatry 19:78PubMedPubMedCentralCrossRefGoogle Scholar
  9. Chan KW, Lee TM, Siu AM, Wong DP, Kam CM, Tsang SK, Chan CC (2013) Effects of chronic ketamine use on frontal and medial temporal cognition. Addict Behav 38:2128–2132PubMedPubMedCentralCrossRefGoogle Scholar
  10. Chang H, Huang MC, Chen LY (2016) Major depressive disorder induced by chronic ketamine abuse: a case report. Prim Care Companion CNS Disord:18Google Scholar
  11. Cheetham A, Allen NB, Yucel M, Lubman DI (2010) The role of affective dysregulation in drug addiction. Clin Psychol Rev 30:621–634PubMedCrossRefGoogle Scholar
  12. Chen LY, Chen CK, Chen CH, Chang HM, Huang MC, Xu K (2020) Association of craving and depressive symptoms in ketamine-dependent patients undergoing withdrawal treatment. Am J Addict 29(1):43–50PubMedCrossRefGoogle Scholar
  13. Chen WJ, Fu TC, Ting TT, Huang WL, Tang GM, Hsiao CK, Chen CY (2009) Use of ecstasy and other psychoactive substances among school-attending adolescents in Taiwan: national surveys 2004–2006. BMC Public Health 9:27PubMedPubMedCentralCrossRefGoogle Scholar
  14. Chen CH, Lee MH, Chen YC, Lin MF (2011) Ketamine-snorting associated cystitis. J Formos Med Assoc 110:787–791PubMedCrossRefGoogle Scholar
  15. Chen WY, Huang MC, Lin SK (2014) Gender differences in subjective discontinuation symptoms associated with ketamine use. Subst Abuse Treat Prev Policy 9:39PubMedPubMedCentralCrossRefGoogle Scholar
  16. Cheng WC, Ng KM, Chan KK, Mok VK, Cheung BK (2007) Roadside detection of impairment under the influence of ketamine—evaluation of ketamine impairment symptoms with reference to its concentration in oral fluid and urine. Forensic Sci Int 170:51–58PubMedCrossRefGoogle Scholar
  17. Cheng WJ, Chen CH, Chen CK, Huang MC, Pietrzak RH, Krystal JH, Xu K (2018) Similar psychotic and cognitive profile between ketamine dependence with persistent psychosis and schizophrenia. Schizophr Res 199:313–318PubMedPubMedCentralCrossRefGoogle Scholar
  18. Chu PS, Ma WK, Wong SC, Chu RW, Cheng CH, Wong S, Tse JM, Lau FL, Yiu MK, Man CW (2008) The destruction of the lower urinary tract by ketamine abuse: a new syndrome? BJU Int 102:1616–1622CrossRefGoogle Scholar
  19. Cohn AM, Cobb C, Hagman BT, Cameron A, Ehlke S, Mitchell JN (2014) Implicit alcohol cognitions in risky drinking nicotine users with and without co-morbid major depressive disorder. Addict Behav 39:797–802PubMedCrossRefGoogle Scholar
  20. Cottrell AM, Gillatt D (2008) Consider ketamine misuse in patients with urinary symptoms. Practitioner 252:5PubMedGoogle Scholar
  21. Critchlow DG (2006) A case of ketamine dependence with discontinuation symptoms. Addiction 101:1212–1213PubMedCrossRefGoogle Scholar
  22. Curran HV, Monaghan L (2001) In and out of the K-hole: a comparison of the acute and residual effects of ketamine in frequent and infrequent ketamine users. Addiction 96:749–760PubMedCrossRefGoogle Scholar
  23. de Luca MT, Badiani A (2011) Ketamine self-administration in the rat: evidence for a critical role of setting. Psychopharmacology (Berl) 214:549–556CrossRefGoogle Scholar
  24. Dillon P, Copeland J, Jansen K (2003) Patterns of use and harms associated with non-medical ketamine use. Drug Alcohol Depend 69:23–28PubMedCrossRefGoogle Scholar
  25. Domino EF (2010) Taming the ketamine tiger. Anesthesiology 113:678–684Google Scholar
  26. Durieux ME (1995) Inhibition by ketamine of muscarinic acetylcholine receptor function. Anesth Analg 81:57–62PubMedGoogle Scholar
  27. Fan N, Xu K, Ning Y, Rosenheck R, Wang D, Ke X, Ding Y, Sun B, Zhou C, Deng X, Tang W, He H (2016) Profiling the psychotic, depressive and anxiety symptoms in chronic ketamine users. Psychiatry Res 237:311–315PubMedPubMedCentralCrossRefGoogle Scholar
  28. Fang YX, Wang YB, Shi J, Liu ZM, Lu L (2006) Recent trends in drug abuse in China. Acta Pharmacol Sin 27:140–144PubMedPubMedCentralCrossRefGoogle Scholar
  29. Fine J, Finestone SC (1973) Sensory disturbances following ketamine anesthesia: recurrent hallucinations. Anesth Analg 52:428–430PubMedCrossRefGoogle Scholar
  30. Goyal S, Ambekar A, Ray R (2014) Ketamine dependence in an anesthesiologist: an occupational hazard? Indian J Psychol Med 36:335–337PubMedPubMedCentralCrossRefGoogle Scholar
  31. Hedden SL, Martins SS, Malcolm RJ, Floyd L, Cavanaugh CE, Latimer WW (2010) Patterns of illegal drug use among an adult alcohol dependent population: results from the National Survey on Drug Use and Health. Drug Alcohol Depend 106:119–125PubMedCrossRefGoogle Scholar
  32. Huang PW, Meng E, Cha TL, Sun GH, Yu DS, Chang SY (2011) Walking-stick ureters’ in ketamine abuse. Kidney Int 80:895PubMedCrossRefGoogle Scholar
  33. Huang MC, Lin SK, Chen CK (2014) A roller coaster from methamphetamine to ketamine. Taiwan J Psychiatry (Taipei) 28:217–231Google Scholar
  34. Huang MC, Chen LY, Chen CK, Lin SK (2016) Potential benefit of lamotrigine in managing ketamine use disorder. Med Hypotheses 87:97–100PubMedCrossRefPubMedCentralGoogle Scholar
  35. Huang MC, Chen LY, Chang HM, Liang XY, Chen CK, Cheng WJ, Xu K (2018) Decreased blood levels of oxytocin in ketamine-dependent patients during early abstinence. Front Psych 9:633CrossRefGoogle Scholar
  36. Huang MC, Chen CH, Chen LY, Chang HM, Chen CK, Lin SK, Xu K (2019) Chronic ketamine abuse is associated with orexin-A reduction and ACTH elevation. Psychopharmacology (Berl)Google Scholar
  37. Hurt PH, Ritchie EC (1994) A case of ketamine dependence. Am J Psychiatry 151:779PubMedPubMedCentralGoogle Scholar
  38. Jansen KL (1990) Ketamine—can chronic use impair memory? Int J Addict 25:133–139PubMedCrossRefPubMedCentralGoogle Scholar
  39. Jansen KL (1993) Non-medical use of ketamine. BMJ 306:601–602PubMedPubMedCentralCrossRefGoogle Scholar
  40. Jansen KL (2000) A review of the nonmedical use of ketamine: use, users and consequences. J Psychoactive Drugs 32:419–433PubMedCrossRefPubMedCentralGoogle Scholar
  41. Jansen KL, Rracot-Cankovic R (2001) The nonmedical use of ketamine, part two: a review of problem use and dependence. J Psychoactive Drugs 33:151–158PubMedCrossRefGoogle Scholar
  42. Javitt DC, Zukin SR, Heresco-Levy U, Umbricht D (2012) Has an angel shown the way? Etiological and therapeutic implications of the PCP/NMDA model of schizophrenia. Schizophr Bull 38:958–966PubMedPubMedCentralCrossRefGoogle Scholar
  43. Kalsi SS, Wood DM, Dargan PI (2011) The epidemiology and patterns of acute and chronic toxicity associated with recreational ketamine use. Emerg Health Threats J 4:7107PubMedCrossRefGoogle Scholar
  44. Kamaya H, Krishna PR (1987) Ketamine addiction. Anesthesiology 67:861–862PubMedCrossRefGoogle Scholar
  45. Kittelberger K, Hur EE, Sazegar S, Keshavan V, Kocsis B (2012) Comparison of the effects of acute and chronic administration of ketamine on hippocampal oscillations: relevance for the NMDA receptor hypofunction model of schizophrenia. Brain Struct Funct 217:395–409PubMedCrossRefGoogle Scholar
  46. Kleinloog D, Uit Den Boogaard A, Dahan A, Mooren R, Klaassen E, Stevens J, Freijer J, Van Gerven J (2015) Optimizing the glutamatergic challenge model for psychosis, using S+ −ketamine to induce psychomimetic symptoms in healthy volunteers. J Psychopharmacol 29:401–413PubMedCrossRefGoogle Scholar
  47. Krystal JH, Karper LP, Seibyl JP, Freeman GK, Delaney R, Bremner JD, Heninger GR, Bowers MB Jr, Charney DS (1994) Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses. Arch Gen Psychiatry 51:199–214PubMedPubMedCentralCrossRefGoogle Scholar
  48. Krystal JH, D’Souza DC, Mathalon D, Perry E, Belger A, Hoffman R (2003) NMDA receptor antagonist effects, cortical glutamatergic function, and schizophrenia: toward a paradigm shift in medication development. Psychopharmacology (Berl) 169:215–233CrossRefGoogle Scholar
  49. Krystal JH, Sanacora G, Duman RS (2013) Rapid-acting glutamatergic antidepressants: the path to ketamine and beyond. Biol Psychiatry 73:1133–1141PubMedPubMedCentralCrossRefGoogle Scholar
  50. Lahti AC, Weiler MA, Tamara Michaelidis BA, Parwani A, Tamminga CA (2001) Effects of ketamine in normal and schizophrenic volunteers. Neuropsychopharmacology 25:455–467PubMedCrossRefGoogle Scholar
  51. Leung KS, Li JH, Tsay WI, Callahan C, Liu SF, Hsu J, Hoffer L, Cottler LB (2008) Dinosaur girls, candy girls, and trinity: voices of Taiwanese club drug users. J Ethn Subst Abuse 7:237–257PubMedPubMedCentralCrossRefGoogle Scholar
  52. Li L, Vlisides PE (2016) Ketamine: 50 years of modulating the mind. Front Hum Neurosci 10:612PubMedPubMedCentralGoogle Scholar
  53. Li JH, Vicknasingam B, Cheung YW, Zhou W, Nurhidayat AW, Jarlais DC, Schottenfeld R (2011) To use or not to use: an update on licit and illicit ketamine use. Subst Abuse Rehabil 2:11–20PubMedPubMedCentralCrossRefGoogle Scholar
  54. Liang HJ, Tang KL, Chan F, Ungvari GS, Tang WK (2015) Ketamine users have high rates of psychosis and/or depression. J Addict Nurs 26:8–13PubMedCrossRefGoogle Scholar
  55. Liao Y, Tang J, Ma M, Wu Z, Yang M, Wang X, Liu T, Chen X, Fletcher PC, Hao W (2010) Frontal white matter abnormalities following chronic ketamine use: a diffusion tensor imaging study. Brain 133:2115–2122CrossRefGoogle Scholar
  56. Liao Y, Tang J, Corlett PR, Wang X, Yang M, Chen H, Liu T, Chen X, Hao W, Fletcher PC (2011) Reduced dorsal prefrontal gray matter after chronic ketamine use. Biol Psychiatry 69:42–48CrossRefGoogle Scholar
  57. Lin PC, Lane HY, Lin CH (2016) Spontaneous remission of ketamine withdrawal-related depression. Clin Neuropharmacol 39:51–52PubMedCrossRefGoogle Scholar
  58. Liu Y, Lin D, Wu B, Zhou W (2016) Ketamine abuse potential and use disorder. Brain Res Bull 126:68–73PubMedPubMedCentralCrossRefGoogle Scholar
  59. Livingston A, Waterman AE (1978) The development of tolerance to ketamine in rats and the significance of hepatic metabolism. Br J Pharmacol 64:63–69PubMedPubMedCentralCrossRefGoogle Scholar
  60. Lua AC, Lin HR, Tseng YT, Hu AR, Yeh PC (2003) Profiles of urine samples from participants at rave party in Taiwan: prevalence of ketamine and MDMA abuse. Forensic Sci Int 136:47–51PubMedCrossRefGoogle Scholar
  61. Moore NN, Bostwick JM (1999) Ketamine dependence in anesthesia providers. Psychosomatics 40:356–359PubMedCrossRefGoogle Scholar
  62. Morgan CJ, Monaghan L, Curran HV (2004) Beyond the K-hole: a 3-year longitudinal investigation of the cognitive and subjective effects of ketamine in recreational users who have substantially reduced their use of the drug. Addiction 99:1450–1461PubMedPubMedCentralCrossRefGoogle Scholar
  63. Morgan CJ, Rees H, Curran HV (2008) Attentional bias to incentive stimuli in frequent ketamine users. Psychol Med 38:1331–1340PubMedCrossRefGoogle Scholar
  64. Morgan CJ, Muetzelfeldt L, Curran HV (2009) Ketamine use, cognition and psychological wellbeing: a comparison of frequent, infrequent and ex-users with polydrug and non-using controls. Addiction 104:77–87CrossRefGoogle Scholar
  65. Morgan CJ, Muetzelfeldt L, Curran HV (2010) Consequences of chronic ketamine self-administration upon neurocognitive function and psychological wellbeing: a 1-year longitudinal study. Addiction 105:121–133PubMedCrossRefGoogle Scholar
  66. Morgan CJ, Curran HV, Independent Scientific Committee on Drugs (2012) Ketamine use: a review. Addiction 107:27–38PubMedPubMedCentralCrossRefGoogle Scholar
  67. Muetzelfeldt L, Kamboj SK, Rees H, Taylor J, Morgan CJ, Curran HV (2008) Journey through the K-hole: phenomenological aspects of ketamine use. Drug Alcohol Depend 95:219–229PubMedCrossRefGoogle Scholar
  68. Murrough JW, Iosifescu DV, Chang LC, Al Jurdi RK, Green CE, Perez AM, Iqbal S, Pillemer S, Foulkes A, Shah A, Charney DS, Mathew SJ (2013) Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial. Am J Psychiatry 170:1134–1142PubMedPubMedCentralCrossRefGoogle Scholar
  69. Ng SH, Tse ML, Ng HW, Lau FL (2010) Emergency department presentation of ketamine abusers in Hong Kong: a review of 233 cases. Hong Kong Med J 16:6–11PubMedGoogle Scholar
  70. O’Brien CP (2005) Anticraving medications for relapse prevention: a possible new class of psychoactive medications. Am J Psychiatry 162:1423–1431PubMedCrossRefGoogle Scholar
  71. Olney JW, Wozniak DF, Jevtovic-Todorovic V, Farber NB, Bittigau P, Ikonomidou C (2002) Drug-induced apoptotic neurodegeneration in the developing brain. Brain Pathol 12:488–498PubMedCrossRefGoogle Scholar
  72. Pal HR, Berry N, Kumar R, Ray R (2002) Ketamine dependence. Anaesth Intensive Care 30:382–384PubMedCrossRefGoogle Scholar
  73. Petersen RC, Stillman RC (1978) Phencyclidine: an overview. NIDA Res Monogr:1–17Google Scholar
  74. Rabiner EA (2007) Imaging of striatal dopamine release elicited with NMDA antagonists: is there anything there to be seen? J Psychopharmacol 21:253–258PubMedCrossRefGoogle Scholar
  75. Reier CE (1971) Ketamine—“dissociative agent” or hallucinogen? N Engl J Med 284:791–792PubMedGoogle Scholar
  76. Rounsaville BJ (2004) Treatment of cocaine dependence and depression. Biol Psychiatry 56:803–809PubMedCrossRefGoogle Scholar
  77. Shahani R, Streutker C, Dickson B, Stewart RJ (2007) Ketamine-associated ulcerative cystitis: a new clinical entity. Urology 69:810–812PubMedPubMedCentralCrossRefGoogle Scholar
  78. Smith GS, Schloesser R, Brodie JD, Dewey SL, Logan J, Vitkun SA, Simkowitz P, Hurley A, Cooper T, Volkow ND, Cancro R (1998) Glutamate modulation of dopamine measured in vivo with positron emission tomography (PET) and 11C-raclopride in normal human subjects. Neuropsychopharmacology 18:18–25PubMedCrossRefPubMedCentralGoogle Scholar
  79. Stone JM, Pepper F, Fam J, Furby H, Hughes E, Morgan C, Howes OD (2014) Glutamate, N-acetyl aspartate and psychotic symptoms in chronic ketamine users. Psychopharmacology (Berl) 231:2107–2116CrossRefGoogle Scholar
  80. Strong CE, Schoepfer KJ, Dossat AM, Saland SK, Wright KN, Kabbaj M (2017) Locomotor sensitization to intermittent ketamine administration is associated with nucleus accumbens plasticity in male and female rats. Neuropharmacology 121:195–203PubMedPubMedCentralCrossRefGoogle Scholar
  81. Sun L, Li Q, Li Q, Zhang Y, Liu D, Jiang H, Pan F, Yew DT (2014) Chronic ketamine exposure induces permanent impairment of brain functions in adolescent cynomolgus monkeys. Addict Biol 19:185–194PubMedPubMedCentralCrossRefGoogle Scholar
  82. Tang WK, Liang HJ, Lau CG, Tang A, Ungvari GS (2013) Relationship between cognitive impairment and depressive symptoms in current ketamine users. J Stud Alcohol Drugs 74:460–468PubMedPubMedCentralCrossRefGoogle Scholar
  83. Tang J, Morgan HL, Liao Y, Corlett PR, Wang D, Li H, Tang Y, Chen J, Liu T, Hao W, Fletcher PC, Chen X (2015a) Chronic administration of ketamine mimics the perturbed sense of body ownership associated with schizophrenia. Psychopharmacology (Berl) 232:1515–1526CrossRefGoogle Scholar
  84. Tang WK, Morgan CJ, Lau GC, Liang HJ, Tang A, Ungvari GS (2015b) Psychiatric morbidity in ketamine users attending counselling and youth outreach services. Subst Abus 36:67–74PubMedCrossRefGoogle Scholar
  85. Trujillo KA, Smith ML, Sullivan B, Heller CY, Garcia C, Bates M (2011) The neurobehavioral pharmacology of ketamine: implications for drug abuse, addiction, and psychiatric disorders. ILAR J 52:366–378PubMedPubMedCentralCrossRefGoogle Scholar
  86. UNODC (2019) World Drug Report United Nations publicationGoogle Scholar
  87. Venniro M, Mutti A, Chiamulera C (2015) Pharmacological and non-pharmacological factors that regulate the acquisition of ketamine self-administration in rats. Psychopharmacology (Berl) 232:4505–4514CrossRefGoogle Scholar
  88. Vollenweider FX, Leenders KL, Scharfetter C, Antonini A, Maguire P, Missimer J, Angst J (1997) Metabolic hyperfrontality and psychopathology in the ketamine model of psychosis using positron emission tomography (PET) and [18F]fluorodeoxyglucose (FDG). Eur Neuropsychopharmacol 7:9–24PubMedCrossRefGoogle Scholar
  89. Wang C, Zheng D, Xu J, Lam W, Yew DT (2013) Brain damages in ketamine addicts as revealed by magnetic resonance imaging. Front Neuroanat 7:23PubMedPubMedCentralCrossRefGoogle Scholar
  90. Wang LJ, Chen CK, Lin SK, Chen YC, Xu K, Huang MC (2018) Cognitive profile of ketamine-dependent patients compared with methamphetamine-dependent patients and healthy controls. Psychopharmacology (Berl) 235:2113–2121CrossRefGoogle Scholar
  91. White PF, Way WL, Trevor AJ (1982) Ketamine—its pharmacology and therapeutic uses. Anesthesiology 56:119–136PubMedCrossRefGoogle Scholar
  92. Wong SW, Lee KF, Wong J, Ng WW, Cheung YS, Lai PB (2009) Dilated common bile ducts mimicking choledochal cysts in ketamine abusers. Hong Kong Med J 15:53–56PubMedGoogle Scholar
  93. Xu K, Krystal JH, Ning Y, Chen Da C, He H, Wang D, Ke X, Zhang X, Ding Y, Liu Y, Gueorguieva R, Wang Z, Limoncelli D, Pietrzak RH, Petrakis IL, Zhang X, Fan N (2015) Preliminary analysis of positive and negative syndrome scale in ketamine-associated psychosis in comparison with schizophrenia. J Psychiatr Res 61:64–72PubMedCrossRefGoogle Scholar
  94. Yen CF, Hsu SY, Cheng CP (2007) Polysubstance use and its correlates in adolescent ecstasy users in Taiwan. Addict Behav 32:2286–2291PubMedCrossRefGoogle Scholar
  95. Yu WL, Cho CC, Lung PF, Hung EH, Hui JW, Chau HH, Chan AW, Ahuja AT (2014) Ketamine-related cholangiopathy: a retrospective study on clinical and imaging findings. Abdom Imaging 39:1241–1246PubMedCrossRefGoogle Scholar
  96. Zarate CA Jr, Singh JB, Carlson PJ, Brutsche NE, Ameli R, Luckenbaugh DA, Charney DS, Manji HK (2006) A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression. Arch Gen Psychiatry 63:856–864PubMedPubMedCentralCrossRefGoogle Scholar
  97. Zhang Y, Xu Z, Zhang S, Desrosiers A, Schottenfeld RS, Chawarski MC (2014) Profiles of psychiatric symptoms among amphetamine type stimulant and ketamine using inpatients in Wuhan. China J Psychiatr Res 53:99–102PubMedCrossRefGoogle Scholar

Copyright information

© Springer Nature Singapore Pte Ltd. 2020

Authors and Affiliations

  1. 1.Department of Addiction SciencesTaipei City Psychiatric Center, Taipei City HospitalTaipeiTaiwan
  2. 2.Department of PsychiatrySchool of Medicine, College of Medicine, Taipei Medical UniversityTaipeiTaiwan

Personalised recommendations